McDermott Represents lifespin on a Strategic Collaboration with Acibadem in the Field of AI-based Metabolomics Precision Medicine - McDermott Will & Emery

McDermott Represents lifespin on a Strategic Collaboration with Acibadem in the Field of AI-based Metabolomics Precision Medicine

Overview


Frankfurt, May 29, 2024 – McDermott Will & Emery represents German lifespin GmbH, a pioneer in health status detection software, on forming a partnership with Acibadem University (ACU) and Acibadem Healthcare Group (AHG). The collaboration serves to launch a precision medicine initiative in the area of personalized healthcare.

Under the collaboration agreement, lifespin and ACU will combine their expertise to establish a state-of-the-art, AI-based metabolomics precision medicine platform. lifespin will offer their services across ACU’s extensive network through a Software as a Service (SaaS) model.

lifespin GmbH is a deep-data company that develops omni-intelligent health status assessment software enabled by proprietary AI algorithms. lifespin has built one of the largest databases of metabolomic health profiles across 240,000+ healthy and diseased individuals covering multiple age and biological sex groups as well as specific diseases in neurology, oncology, and inflammation.

Acibadem Healthcare Group was established in 1991, rapidly becoming one of the leading institutions in Turkey within the field of private healthcare services. Acibadem is part of the world’s second largest healthcare chain with its 24 hospitals and 15 outpatient clinics, as well as 7 cancer centers.

The McDermott team was led by partner Deniz Tschammler and comprised partners Jana Grieb and Florian Lechner, counsel Markus Fischer as well as associates Lea Hachmeister and Katharina Hoffmeister.

Media Contacts